A conformation-sensitive monoclonal antibody against the A2 domain of von willebrand factor reduces its proteolysis by ADAMTS13

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Zhang, Jingyu ^a,b   Ma, Zhenni ^a   Dong, Ningzheng ^a   Liu, Fang ^c   Su, Jian ^a   Zhao, Yiming ^a   Shen, Fei ^a   Wang, Anyou ^a   Ruan, Changgeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1C1E7; MONOCLONAL ANTIBODY 75H4B12; MONOCLONAL ANTIBODY SZ125; MONOCLONAL ANTIBODY SZ129; MONOCLONAL ANTIBODY SZ13; MONOCLONAL ANTIBODY SZ130; MONOCLONAL ANTIBODY SZ29; MONOCLONAL ANTIBODY SZ34; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN UNFOLDING; SHEAR STRESS; SPECIES COMPARISON; WESTERN BLOTTING; CHEMISTRY; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION;

MURINAE;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 79960148169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022157     Document Type: Article

References (33)

1. Ruggeri ZM, (1991) Structure and function of von Willebrand factor: relationship to von Willebrand's disease. Mayo Clin Proc 66: 847-861.
2. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, et al. (1989) Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol 73: 93-99.
3. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM, (1990) Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A 87: 6306-6310.
4. Furlan M, Robles R, Lämmle B, (1996) Partial purification of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223-4234.
5. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494.
6. Tsai HM, Lian EC, (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594.
7. Sadler JE, (2008) Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112: 11-18.
8. Hassenpflug WA, Budde U, Obser T, Angerhaus D, Drewke E, et al. (2006) Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 107: 2339-2345.
9. Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, et al. (2007) Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost 5: 321-328.
10. Nishio K, Anderson PJ, Zheng XL, Sadler JE, (2004) Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 101: 10578-10583.
11. Skipwith CG, Cao W, Zheng XL, (2010) Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 285: 28596-28603.
12. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE, (2008) Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 111: 651-657.
13. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, et al. (2004) Role of Thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279: 21439-21448.
14. Bonnefoy A, Daenens K, Feys HB, De Vos R, Vandervoort P, et al. (2006) Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13. Blood 107: 955-964.
15. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, et al. (1997) Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 89: 1954-1962.
16. Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, et al. (2009) A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 114: 2819-2828.
17. Cruz MA, Whitelock JL, Dong JF, (2003) Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand factor A2 domain polypeptide as substrate. Thromb Haemost 90: 1234-1239.
18. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA, (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324: 1330-1334.
19. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, et al. (2009) Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A 106: 9226-9231.
20. Dong JF, (2005) Cleavage of ultra-large von Willebrand factor by ADAMTS-13 flow conditions. J Thromb Haemost 3: 1710-1716.
21. Kokame K, Matsumoto M, Fujimura Y, Miyata T, (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103: 607-612.
22. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA, (2008) N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 111: 3042-3049.
23. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL, (2008) Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 105: 7416-7421.
24. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, et al. (2005) Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 106: 4139-4145.
25. Hoylaerts MF, Viaene A, Thys C, Deckmyn H, Vermylen J, (2001) Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces. J Thromb Thrombolysis 12: 249-262.
26. Shen F, Dong N, Xie L, Fan L, Zhao Y, et al. (2008) Preparation and characterization of monoclonal antibodies against human von Willebrand factor A1 domain. Soochow University Journal of Medical Science 28: 234-236.
27. Zhao Y, Dong N, Shen F, Xie L, He Y, et al. (2007) Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost 5: 1963-1970.
28. Ruan C, Xi X, Gu J, (1986) Studies on monoclonal antibodies to human von Willebrand factor. Zhonghua Nei Ke Za Zhi 25: 547-550.
29. Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE, (1992) The mutation Arg (53)-Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 79: 563-567.
30. Tsai HM, (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87: 4235-4244.
31. Su J, Bai X, Gao WQ, Ruan CG, (2005) A2 domain of human von Willebrand factor expressed in E. coli and its biological activity. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13: 1090-1093.
32. Liang Y, Wan Y, Qiu LW, Zhou J, Ni B, et al. (2005) Comprehensive antibody epitope mapping of the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus: insight into the humoral immunity of SARS. Clin Chem 51: 1382-1396.
33. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME, (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77: 305-319.